Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Assets (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Other Non-Current Assets for 4 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 28.78% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 28.78% decrease, with the full-year FY2024 number at $2.0 million, down 19.89% from a year prior.
  • Other Non-Current Assets was $1.6 million for Q3 2025 at Centessa Pharmaceuticals, down from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.0 million in Q1 2023 to a low of $619000.0 in Q1 2022.
  • A 4-year average of $2.1 million and a median of $1.9 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 875.77% in 2023, then crashed 68.82% in 2024.
  • Centessa Pharmaceuticals' Other Non-Current Assets stood at $1.9 million in 2022, then soared by 35.85% to $2.6 million in 2023, then fell by 19.89% to $2.0 million in 2024, then dropped by 22.34% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Other Non-Current Assets are $1.6 million (Q3 2025), $1.7 million (Q2 2025), and $1.9 million (Q1 2025).